Mínimo 3 entidades de 3 países
Neurodegenerative diseases are a high burden for patients, caregivers, health systems and society. Given the limitations with current therapeutic solutions, including that they primarily address symptoms rather than underlying causes and can have serious side effects, together with the increasing prevalence of neurodegenerative diseases in an aging population, there is a huge need to develop more innovative, safer and more effective therapeutic solutions for these diseases. g.
Ver en el portal de la ComisiónFuente:Portal Funding & Tenders (Comisión Europea), actualizado el 31 oct 2026